May 2026– date –
-
XellSmart Initiates Phase II Trial for iPSC-Based Parkinson’s Therapy Following Encouraging Phase I Results
The Regen Report USA Overview XellSmart has advanced its iPSC-derived cellular therapy for Parkinson's disease into Phase II clinical trials, driven by positive safety and preliminary efficacy data from its Phase I study. This critical p... -
NIH-Funded Research Achieves Breakthrough in Shrinking CRISPR Systems for Enhanced In Vivo Precision Delivery
European AIDS Treatment Group (EATG) News USA Overview NIH-funded research has successfully developed miniaturized CRISPR-Cas gene editing systems, overcoming a significant hurdle in in vivo delivery for traditional larger systems. This ... -
Cell-Easy Launches Large-Scale iPSC-Derived Beta Cell Program to Address Manufacturing Bottlenecks for Diabetes Therapy
BioInformant USA Overview Cell-Easy has initiated a new program focused on scaling up the manufacturing of iPSC-derived beta cells, addressing a critical bottleneck for diabetes therapies. This initiative aims to establish a stable, high... -
Americord Registry Spotlights Latest Breakthroughs in iPSC Clinical Trials Across Diverse Disease Areas
Americord Registry USA Overview Americord Registry has released a comprehensive report detailing the latest advancements in iPSC clinical trials, highlighting expanding applications in neurological and ophthalmic conditions. The report i... -
Locus Cell Establishes Large-Scale Manufacturing Process for Human Umbilical Cord Mesenchymal Stem Cells Using CellFiber® Technology
PR Times Japan Overview Locus Cell Inc., in collaboration with CellFiber Inc., has announced the successful establishment of a large-scale, high-efficiency manufacturing process for human umbilical cord-derived mesenchymal stem cells (UC... -
K Pharma Advances Diverse Pipeline: Six iPSC-Based Drug Discovery Programs and Five Regenerative Medicine Projects in Progress
Kabutan.jp Japan Overview K Pharma's Q1 financial report reveals steady progress across its iPSC-based drug discovery and regenerative medicine divisions. The company is actively developing six pipelines in drug discovery and five pipeli... -
Japan’s PMDA Enhances Regulatory Framework for Regenerative Medicine Products Amidst Continuous Updates
独立行政法人 医薬品医療機器総合機構 (PMDA) Japan Overview Japan's Pharmaceuticals and Medical Devices Agency (PMDA) implemented several regulatory updates from May 8-15, 2026, pertaining to pharmaceuticals and regenerative medicine produ... -
Japan Approves First Regenerative Medicine Product for Meniscus Injury; University of Tokyo Uncovers T-cell Reprogramming Mechanism
国立研究開発法人日本医療研究開発機構 (AMED) Japan Overview Japan's AMED announced the approval of Fujifilm Toyama Chemical's "Saviskas Injection," the nation's first regenerative medicine product for meniscus injuries, on May 8, 2026. Si... -
Japan Approves Edostiladrin Gene Therapy for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer, Offering Bladder Preservation
Oncolo.jp Japan Overview Ferring Pharmaceuticals has received manufacturing and marketing approval in Japan for Edostiladrin (nadofaragene firadenovec), a gene therapy for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NM... -
Japan Approves Pricing for World’s First iPSC-Derived Product, Amchepry, Signaling New Era for Regenerative Medicine
薬事日報 Japan Overview Japan's Central Social Insurance Medical Council has approved the official drug pricing for three new regenerative medicine products, including Sumitomo Pharma's iPSC-derived dopamine neural progenitor cells, Amch...
